Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic Islet Cells on Omentum for T1D
NCT02213003Phase 2Completed
- Start
- Sep 2014
- Primary completion
- Jun 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of donislecel in type 1 diabetes mellitus (T1D). Primary endpoints: Proportion of subjects with HbA1c <= 6.5% and free of severe hypoglycemic events at 1 year and Patient safety throughout all stages of the trial at 1 year. Started Sep 2014; status: completed.
02
Drugs
donislecel
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02213003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02213003.